rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kenneth Hoberman

Director

Company insider

Files Form 4 as: Director, TG Therapeutics; Director, Nuvectis Pharma; Chief Operating Officer, Stemline Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
101
Buys
2
Sells
42
Bought
$126K
Sold
$5.8M
Companies
3
Companies where not an officer
2
First trade
16 Dec 2009
Last trade
11 Jun 2026
Last filed
15 Jun 2026

Companies traded

Where they are an officer
Stemline TherapeuticsOfficer · last 10 Jun 20201 buy · 42 sells
Everywhere else they filed: board seats, 10% stakes, other companies
NVCT Nuvectis PharmaDirector · Biotechnology · last 11 Jun 20261 buy · 0 sells
TGTX TG TherapeuticsDirector · Biotechnology · last 11 Jun 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
11 Jun 2026filed 15 Jun 2026TGTX TG Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—8,325 at $0.00filing
11 Jun 2026filed 15 Jun 2026TGTX TG Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—8,325 at $0.00filing
11 Jun 2026filed 12 Jun 2026NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Code A—35,000 at $0.00filing
11 Jun 2026filed 12 Jun 2026NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Code A—35,000 at $0.00filing
12 Jun 2025filed 16 Jun 2025TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—14,718 at $0.00filing
12 Jun 2025filed 12 Jun 2025NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
19 Jun 2024filed 20 Jun 2024TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—22,250 at $0.00filing
13 Jun 2024filed 13 Jun 2024NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
28 Sep 2023filed 29 Sep 2023TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
16 Jun 2023filed 20 Jun 2023NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Code A—18,000 at $0.00filing
20 Jul 2022filed 22 Jul 2022TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—43,732 at $0.00filing
12 May 2022filed 16 May 2022NVCT Nuvectis PharmaBiotechnologySEC FORM 4 Bought$104K6,000 at $17.40filing
1 Apr 2022filed 5 Apr 2022NVCT Nuvectis Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
18 Jun 2021filed 22 Jun 2021TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
22 Jun 2020filed 24 Jun 2020TGTX TG TherapeuticsBiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
10 Jun 2020filed 10 Jun 2020Stemline Therapeuticsoption or derivativeSEC FORM 4 Code D—25,000filing
10 Jun 2020filed 10 Jun 2020Stemline Therapeuticsoption or derivativeSEC FORM 4 Code D—44,058filing
10 Jun 2020filed 10 Jun 2020Stemline TherapeuticsSEC FORM 4 Code A—600,000 at $0.00filing
10 Jun 2020filed 10 Jun 2020Stemline TherapeuticsSEC FORM 4 Code U—1,374,352filing
10 Mar 2020filed 13 Mar 2020Stemline TherapeuticsSEC FORM 4 Sold$82K16,704 at $4.91filing

News

Nuvectis Pharma (NASDAQ:NVCT) Stock Falls 6.8% – Here's WhyNVCT · themarketsdaily.com · 15 Oct 2026

0 headlines in the last 90 days name Kenneth Hoberman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care1
Not placed43

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.